

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



北京昭衍新藥研究中心股份有限公司  
(a joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 6127)

2022

This announcement is made by JOINN Laboratories (China) Co., Ltd. (the “Company”) pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Hong Kong Listing Rules.

From January to June 2022, the net profit attributable to the shareholders of the Company (RMB340.9570 million to RMB402.4510 million) will increase by approximately RMB187.2221 million to RMB248.7161 million, representing a period-on period increase of approximately 121.8% to 161.8% as compared with the data in the financial statements for the corresponding period of last year;

(I) Period of estimated results

From 1 January 2022 to 30 June 2022.

(II) Estimated results

The preliminary estimates made by the Company's finance department are as follows:

1. It is expected that the net profit attributable to the shareholders of the Company for the period from January to June 2022 will increase from approximately RMB187.2221 million to RMB248.7161 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 121.8% to 161.8%.

2. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the period from January to June 2022 will increase by approximately RMB186.7206 million to RMB248.2145 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 144.3% to 191.9%.

(III) The estimated results have not been audited by certified public accountants.

Net profit attributable to shareholders of the Company for the corresponding period of last year: RMB153.7349 million. Net profit attributable to shareholders of the Company after deducting non-recurring profit or loss: RMB129.3628 million; earnings per share: RMB0.6.

- (I) The financial increment was mainly attributable to the following factors: (i) the Company continues to maintain its advanced and leading position in the field of innovative drugs, especially on the biomolecule drug evaluation and continues to develop new evaluation methods and technical means to provide strong research and development support for the innovative pharmaceutical companies, which is trusted by both new and old customers; (ii) the Company has further improved its utilization rate of its facilities, the newly added facilities of JOINN (Suzhou) has played a vital role. Furthermore, the technical team continued to develop to ensure the efficient completion of the orders on hand; (iii) the Company has strengthened the layout of the upstream industry chain, providing strong support for the achievement of the Company's results; (iv) the Company's capital management causes positive impact on overall performance.
- (II) Impact of non-operating profit or loss. It was mainly due to factors such as government subsidies, gains on financial assets held for trading and acquisition of negative goodwill. The non-recurring gains and losses after income tax was approximately RMB24.90 million, which is the same for the corresponding period of last year.

There are no material uncertainties affecting the accuracy of the estimated results.

The financial data contained in this results forecast is prepared in accordance with the China Accounting Standards for Business Enterprises and the estimated data is only preliminary accounting figures. The specific and accurate financial data shall refer to the unaudited 2022 interim results announcement and the 2022 Interim Report prepared in accordance with the China Accounting Standards for Business Enterprises or the International Financial Reporting Standards officially disclosed by the Company. Investors are advised to pay attention to investment risks.

By order of the Board

*Chairperson*

Hong Kong, July 14, 2022

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, Mr. Gu Xiaolei as a non-executive Director, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*